- Home
- KALV
as 09-16-2025 2:33pm EST
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 796.4M | IPO Year: | N/A |
| Target Price: | $26.43 | AVG Volume (30 days): | 986.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.30 - $17.28 | Next Earning Date: | 09-11-2025 |
| Revenue: | $1,426,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 221.95% |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Sep 8 '25 | Sell | $15.84 | 7,294 | $115,536.96 | 395,189 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Aug 25 '25 | Sell | $13.42 | 1,954 | $26,222.68 | 132,052 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Aug 25 '25 | Sell | $13.42 | 2,336 | $31,349.12 | 122,505 | |
| Sweeny Nicole | KALV | Chief Commercial Officer | Aug 25 '25 | Sell | $13.42 | 1,480 | $19,861.60 | 32,291 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Aug 22 '25 | Sell | $13.22 | 10,940 | $144,657.43 | 395,189 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Aug 22 '25 | Sell | $13.22 | 2,362 | $31,232.25 | 132,052 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Aug 22 '25 | Sell | $13.22 | 2,942 | $38,901.48 | 122,505 | |
| Sweeny Nicole | KALV | Chief Commercial Officer | Aug 22 '25 | Sell | $13.22 | 1,864 | $24,647.30 | 32,291 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Aug 18 '25 | Sell | $13.19 | 4,409 | $58,141.48 | 395,189 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Aug 18 '25 | Sell | $13.19 | 2,649 | $34,932.36 | 132,052 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
CNW Group
3 months ago
Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada
MT Newswires
3 months ago
Sector Update: Health Care Stocks Steady Pre-Bell Thursday
MT Newswires
3 months ago
KalVista Grants Pendopharm Rights to Commercialize its Angioedema Treatment in Canada
Business Wire
3 months ago
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
Investor's Business Daily
3 months ago
How KalVista Pharma Is Taking On A Rare But Deadly Disease
MT Newswires
3 months ago
DRI Healthcare Notes FDA Delay for KalVista's' Sebetralstat New Drug Approval on "Resourcing" Issues
Business Wire
3 months ago
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
BioPharma Dive
3 months ago
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’
Compare KALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.